<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02072967</url>
  </required_header>
  <id_info>
    <org_study_id>RU-BEN-NI-001</org_study_id>
    <nct_id>NCT02072967</nct_id>
  </id_info>
  <brief_title>Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Observational Program for Evaluation of Ribomustin and Rituximab Combined Therapy With Following Rituximab Maintenance of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective multicenter observational non-interventional study to assess routine clinical
      practice of Bendamustine use in the second line therapy of relapsed or refractory indolent
      B-cell non-Hodgkin's lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>90 days post-treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reactions</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">97</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Ribomustin and rituximab</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ribomustin</intervention_name>
    <description>Routine practice</description>
    <arm_group_label>Ribomustin and rituximab</arm_group_label>
    <other_name>bendamustine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Routine practice</description>
    <arm_group_label>Ribomustin and rituximab</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma with planned
        combined Ribomustin and rituximab therapy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Doctor's decision to prescribe Ribomustin and rituximab combined therapy for the
             treatment of relapsed or refractory indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

          -  Informed Consent Form for personal data handling signed by the program participant,
             authorized by the Independent Ethics Committee

          -  Eastern Cooperative Oncology Group (ECOG) status &lt; 2.

          -  Confirmed relapse or disease progression of B-cell CD20+ Non-Hodgkin's Lymphoma
             (lymphocytic, lymphocytoplasmocytic, follicular, marginal zone) after minimum one line
             of iNHL treatment

          -  Patients with relapsed or refractory indolent B-cell Non-Hodgkin's Lymphoma with
             current or planned Ribomustin and rituximab combined therapy with following rituximab
             maintenance therapy

        Exclusion Criteria:

          -  Indolent Non-Hodgkin's Lymphoma transformation

          -  Lymphoma with central nervous system (CNS) involvement

          -  Presence of second malignant tumor.

          -  Currently participating in any clinical trial, and/or has taken an investigational
             drug within 28 days prior to enrollment.

          -  Contraindications for Ribomustin usage in accordance with product label

          -  Contradictions for rituximab usage in accordance with product label
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City Clinical Hospital #8</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Oncology Dispensary/15</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vologda Regional Clinical Hospital #2</name>
      <address>
        <city>Cherepovets</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Oncology Dispensary/35</name>
      <address>
        <city>Irkutsk</city>
        <zip>664035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irkutsk Regional Сlinical Hospital/31</name>
      <address>
        <city>Irkutsk</city>
        <zip>664079</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaluga Regional Clinical Hospital/02</name>
      <address>
        <city>Kaluga</city>
        <zip>248007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>District Cancer center od Khanty -Mansiysk</name>
      <address>
        <city>Khanty-Mansiysk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Сlinical Hospital#7/25</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Сlinical Hospital/12</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adygei Regional Clinical Oncology Dispensary/11</name>
      <address>
        <city>Maykop</city>
        <zip>385017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Medical Surgical Center n.a.I.V.Pyrogov/17</name>
      <address>
        <city>Moscow</city>
        <zip>105203</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>European Medical Center</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RONC n.a.N.N.Blokhin/18</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Сentral Clinical Hospital n.a. Semashko N.A./30</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Scientific Research Oncology Institution n.a.P.A. Gertzen/37</name>
      <address>
        <city>Moscow</city>
        <zip>443099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of Department of Presidential Affairs</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Сlinical Hospital № 12/20</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novosibirsk State Regional Clinical Hospital/23</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Radiology Scientific Center/38</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omsk Regional Clinical Hospital/40</name>
      <address>
        <city>Omsk</city>
        <zip>644111</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Сlinical Hospital#1 n.a.Kabanov A.N./13</name>
      <address>
        <city>Omsk</city>
        <zip>644112</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orenburg State Medical Academy/05</name>
      <address>
        <city>Orenburg</city>
        <zip>460000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov Scientific Research Oncology Institution/01</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Сlinical Oncological Dispensary/22</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Сlinical Hospital#31/08</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military-Medical Academy n.a. Kirova</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Oncological Institution n.a. Petrov N.N./29</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara State Medical University' Clinics/36</name>
      <address>
        <city>Samara</city>
        <zip>443099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Road Clinical Hospital on Rostov-Main Station OAO RZhD/06</name>
      <address>
        <city>Smolensk</city>
        <zip>214025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgut Regional Clinical Hospital</name>
      <address>
        <city>Surgut</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tula Regional Clinical Hospital/21</name>
      <address>
        <city>Tula</city>
        <zip>300053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volgograd Regional Clinical Oncology Dispensary#1/10</name>
      <address>
        <city>Volgograd</city>
        <zip>400138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vologda Regional Clinical Hospital/39</name>
      <address>
        <city>Vologda</city>
        <zip>160002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yekaterinburg Regional Clinical Hospital #1</name>
      <address>
        <city>Yekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakhalin Regional Oncology Dispensary/32</name>
      <address>
        <city>Yuzhno-Sakhalinsk</city>
        <zip>693010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2014</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2014</study_first_posted>
  <last_update_submitted>February 19, 2016</last_update_submitted>
  <last_update_submitted_qc>February 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>Bendamustine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

